| Mr فيليب سكوت
| -- |
| Mr Phil Thomson
| Mr PhilThomson is the Contact person at GlaxoSmithKline PLC, Phil was appointed Senior Vice President, Global Communications in August 2010, Senior Vice President at GlaxoSmithKline PLC - United States in January 2010, Global Communications. He has responsibility for Media Relations, Investor Relations, Corporate Responsibility, Global Community Partnerships, and Internal, Product, and Business Communications. Phil joined Glaxo Wellcome as a commercial trainee in 1996. |
| Ms Stacey Cartwright
| Ms Stacey Cartwright is Board Member at GlaxoSmithKline PLC. Ms. Stacey Cartwright Appointed on 1 April 2011. Stacey joined Burberry Group plc as Chief Financial Officer in 2003 and was appointed Executive Vice President, Chief Financial Officer in June 2008. Previously she held the role of Chief Financial Officer at Egg plc between 1999 and 2003, and from 1988 to 1999 she worked in various finance-related positions at Granada Group plc.Stacey is Chief Executive Officer of the Harvey Nichols Group of Companies. She served as Executive Vice President, Chief Financial Officer of Burberry Group plc until July 2013. Previously she held the role of Chief Financial Officer at Egg plc between 1999 and 2003, and from 1988 to 1999 she worked in various finance-related positions at Granada Group plc. In accordance with the UK Corporate Governance Code, the Board has determined that Stacey has recent and relevant financial experience. The Board has also agreed that she has the appropriate qualifications and background to be an audit committee financial expert as defined by the US Sarbanes-Oxley Act of 2002 |
| Mr Simon Dingemans
| Mr Simon Dingemans is Board Member at GlaxoSmithKline PLC. Mr Dingemans owns 0.0003% in GlaxoSmithKline PLC since February 2015. Mr. Simon Dingemans became Chief Financial Officer in April 2011 after joining as Chief Financial Officer Designate in January 2011. He is a member of the Board and the Corporate Executive Team.Simon joined GSK from Goldman Sachs International where he was a Managing Director and Partner. He joined Goldman Sachs in 1995, becoming Head of UK Investment Banking and later becoming a leader of the European Mergers and Acquisitions business. As part of his role at GSK, Simon is responsible for Global Finance and Core Business Services comprising a number of the company’s key global functions including Finance and Real Estate. He worked with GSK for over a decade prior to joining the company and was closely involved in a number of GSK’s most important strategic projects during that time, including the establishment of ViiV Healthcare. After receiving a Masters degree in Geography from Oxford University in 1985, Simon joined S.G. Warburg Group, the investment banking firm which specialised in mergers and acquisitions, becoming one of its youngest directors in 1994. Simon is a member of the Corporate Development Council for the National Theatre and Chairman of the 100 Group. |
| Mr Roy Anderson
| Mr Roy Anderson is Board Member at GlaxoSmithKline PLC. Mr. Roy Anderson Appointed on 1 October 2007. Sir Roy is Professor of Infectious Disease Epidemiology in the Faculty of Medicine, Imperial College, London. He is a member of the International Advisory Board of Hakluyt & Co Ltd, a Trustee of the Natural History Museum, London, a fellow (and member of the Science Policy Advisory Group) of the Royal Society and a fellow of the Academy of Medical Sciences and the Royal Statistical Society. Sir Roy is a member of the International Advisory Board of the HIV Monitoring Foundation, an Honorary Fellow of the Institute of Actuaries and a Foreign Associate Member of the Institute of Medicine at the US National Academy of Sciences and the French Academy of Sciences. His former positions include Rector of Imperial College and Chief Scientific Adviser at the Ministry of Defence in the UK. |
| Mr Andrew Witty
| Mr Andrew Witty is CEO in GlaxoSmithKline PLC. Mr Witty owns 0.0016% in GlaxoSmithKline PLC since February 2015. Mr. Andrew Witty became Chief Executive Officer of GlaxoSmithKline plc on 21 May 2008. He is a member of the Board and Corporate Executive Team. Andrew joined GSK in 1985. He has worked in the UK, South Africa, the USA and Singapore in various senior roles. In 2003, he was appointed President of GSK Europe and joined GSK’s Corporate Executive Team. In 2003 he was awarded the Public Service Medal by the Government of Singapore and in August 2012 was also awarded the Public Service Star. In the 2012 New Year Honours list, he was awarded a Knighthood for services to the economy and to the UK pharmaceutical industry. Andrew served as the Lead Non-Executive Board Member for the Department for Business, Innovation and Skills to December 2013. He was also President of the European Federation of Pharmaceutical Industries and Associations until June 2013. Andrew is a Member of the UK Prime Minister’s Business Advisory Group and Member of the Global Health Innovation Advisory Board, Imperial College London. He is Chancellor of the University of Nottingham and was appointed to the UK Business Ambassador Group in January 2014. Andrew has a Joint Honours BA in Economics from the University of Nottingham. |
| Mr Tom De Swaan
| Mr Tom De Swaan was Board Member at GlaxoSmithKline PLC between 01 January 2006 and 07 May 2015. Mr. Tom De Swaan Appointed on 1 January 2006. Tom is Chairman of the Audit & Risk Committee. He is Chairman of the Supervisory Board of VanLanschot Bankiers, a member of the board of directors of Zurich Financial Services and a Non-Executive Member of KPMG Europe LLP's Public Interest Committee. Tom is also Vice Chairman of the Supervisory Board and Chairman of the Audit Committee of Royal Ahold and a member of the Supervisory Board of Royal DSM. He was previously a member of the Managing Board and Chief Financial Officer of ABN AMRO.Tom is Chairman of the Supervisory Board of Van Lanschot Bankiers and Chairman of the Board of Directors of Zurich Insurance Group. He is also a member of the Supervisory Board of Royal DSM,and a Senior Adviser to Ondra Partners.The Board has determined that Tom has recent and relevant financial experience, and agreed that he has the appropriate qualifications and background to be an audit committee financial expert. |
| Mr كريسبين ديفز
| -- |
| Mr Christopher Gent
| Mr Christopher Gent is Chairman of GlaxoSmithKline PLC. Mr. Christopher Gent, appointed to the Board on 1 June 2004 and as Chairman on 1 January 2005. Sir Christopher has many years' experience of leading global businesses and a track record of delivering outstanding performance in highly competitive industries. He was appointed Managing Director of Vodafone plc in 1985 and then became its Chief Executive Officer in 1997 until his retirement in 2003. Sir Christopher has many years' experience of leading global businesses and a track record of delivering outstanding performance in highly competitive industries. He was appointed Managing Director of Vodafone plc in 1985 and then became its Chief Executive Officer in 1997 until his retirement in 2003. |
| Mr مارك دونير
| -- |
| Mr Daniel Podolsky
| Mr Daniel Podolsky is Board Member at GlaxoSmithKline PLC. Mr. Daniel Podolsky, appointed on 1 July 2006. Daniel is President of the University of Texas Southwestern Medical Center and holds the Phillip O'Bryan Montgomery, Jr., M.D. Distinguished Presidential Chair in Academic Administration, and the Doris and Bryan Wildenthal Distinguished Chair in Medical Science. He is a member of the Institute of Medicine of the US National Academy of Sciences, a member of the board of the Southwestern Medical Foundation and is a director of Antibe Therapeutics, Inc.Daniel is President of the University of Texas Southwestern Medical Center in Dallas and holds the Philip O’Bryan Montgomery, Jr M.D. Distinguished Presidential Chair in Academic Administration, and the Doris and Bryan Wildenthal Distinguished Chair in Medical Science.Daniel is a member of the National Academy of Medicine at the US National Academy of Sciences, the Council of Teaching Hospitals of the Association of Academic Medical Centers, and sits on the Board of the Southwestern Medical Foundation. He is also a Director of Antibe Therapeutics, Inc., Agilent Technologies, Inc. and a member of the National Academies of Sciences Board on Army Science and Technology. |
| Mr Moncef Slaoui
| Mr Moncef Slaoui is Board Member at GlaxoSmithKline PLC. Mr Slaoui owns 0.0009% in GlaxoSmithKline PLC since February 2015. Dr. Moncef Slaoui Appointed on 17 May 2006. Moncef joined GSK Biologicals in 1988 where he engineered the development of a robust vaccines pipeline and subsequently led Worldwide Business Development for pharmaceuticals before his appointment to lead R&D. Moncef was given overall responsibility for GSK's Oncology Business in 2010, and for GSK Vaccines in 2011. He has a PhD in Molecular Biology and Immunology from Université Libre de Bruxelles.Moncef joined GSK Vaccines in 1988 where he engineered the development of a robust vaccines pipeline. He then led Worldwide Business Development for pharmaceutical products before his appointment to lead R&D in 2006. He was given overall responsibility for GSK’s Oncology Business in 2010; for GSK Vaccines in 2011; and for all Global Franchises in 2012. Moncef has advised the US President’s Council of Advisors on Science and Technology and he was a member of the Board of the Agency for Science, Technology & Research (A*STAR) until January 2011. He has a PhD in Molecular Biology and Immunology from Université Libre de Bruxelles and has published more than 100 scientific papers and presentations. Prior to joining GSK, Moncef was Professor of Immunology at the University of Mons, Belgium. |
| Ms Rachel Lomax
| Ms Rachel Lomax is Board Member at HSBC Holdings PLC. Ms Rachel Lomax joined the HSBC Board of Directors in 2008. She has experience in the public and private sectors, plus a deep knowledge of the operations of the UK government and financial system.Her previous appointments include Deputy Governor, Monetary Stability, at the Bank of England (BoE) and a member of the BoE’s Monetary Policy Committee; Permanent Secretary at the UK Government Departments for Transport and Work and Pensions and the Welsh Office; and Vice President and Chief of Staff to the President of the World Bank.She is the chairman of the International Regulatory Strategy Group and director of TheCityUK; director of Bruegel, a Brussels-based European think tank; non-executive director of Arcus European Infrastructure Fund GP LLP and Heathrow Airport Holdings Limited; member of the Council of Imperial College, London; trustee of the Ditchley Foundation; and President of the Institute of Fiscal Studies. She is also a non-executive director and chairman of the corporate responsibility committee of Serco Group plc.Rachel Lomax, Former Deputy Governor, Monetary Stability at the Bank of England from 2003 to 2008, where she was responsible for monetary assessment and money market operation. Prior to joining the Bank, Ms. Lomax served as Permanent Secretary for the Department of Transport and held the same position at the Department for Work and Pensions (1999 to 2002) and the Welsh Office (1996 to 1999). She served as Vice President and Chief of Staff to the President of the World Bank from 1995 to 1996, and was Head of the Economic and Domestic Secretariat at the Cabinet Office in 1994. Ms. Lomax is an independent, non-executive director of HSBC Holdings plc, The Scottish American Investment Company PLC and BAA Limited. |
| Ms لويز اوتيل فريسكو
| -- |
| Ms جنفياف بيرغر
| -- |
| جان مارك أوت
| -- |
| Ms موراي كيسلر
| -- |
| Ms نورا ميد برونيل
| -- |
| Ms بيتسي هولدن
| -- |
| Mr مارك كوتيفاني
| -- |
